



Relationship between portal hypertension and liver stiffness measurements in the treatment of hepatocellular carcinoma from the surgeon's point of view in the Baveno VII era

Nobuyuki Takemura[^], Norihiro Kokudo

Hepato-Biliary Pancreatic Surgery Division, Department of Surgery, National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan
Correspondence to: Nobuyuki Takemura, MD, PhD, FACS. Director of the Hepato-Biliary Pancreatic Surgery Division, Department of Surgery, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjyuku-ku, Tokyo 162-8655, Japan. Email: ntakemura@hosp.ncgm.go.jp.
Comment on: Thabut D, Kudo M. Treatment of portal hypertension in patients with HCC in the era of Baveno VII. *J Hepatol* 2023;78:658-62.

Keywords: Hepatocellular carcinoma (HCC); portal hypertension (PHT); Baveno VII; hepatectomy; clinically significant portal hypertension (CSPH)

Submitted Nov 13, 2023. Accepted for publication Dec 06, 2023. Published online Jan 05, 2024.

doi: 10.21037/hbsn-23-598

View this article at: <https://dx.doi.org/10.21037/hbsn-23-598>

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide (1). It often arises from the backgrounds of damaged liver due to viral hepatitis, alcoholic, or non-alcoholic liver disease. Although the proportion of patients with HCC of non-hepatitis B and C origins has increased in recent years, hepatitis B and C viruses still cause more than half of all carcinogenesis in patients with HCC (2). Patients with HCC often develop portal hypertension (PHT) from cirrhosis due to the deterioration of the background liver, which proves to be the greatest obstacle to various types of treatments for HCC. The results of the latest consensus meeting to improve the understanding of PHT and disseminate evidence on its diagnosis, natural history, and treatment were published in 2022 as Baveno VII (3). Baveno VII updated the diagnostic criteria for PHT and the definition of clinically significant portal hypertension (CSPH) indicated non-invasive screening for PHT and management of CSPH. However, Baveno VII did not mention PHT associated with HCC. Thabut and Kudo reviewed and recommended the management of PHT in patients with HCC based on the latest data and Baveno VII (4). We respect their work and reviewed their reports with great interest. As hepatologists involved in the daily practice for

HCC and as hepatic surgeons, we would like to make a few comments on their report on hepatectomy and PHT in the era of Baveno VII.

In the Baveno VII consensus, patients with CSPH are recommended to receive prophylactic beta-blockers to prevent worsening of PHT and its associated complications, regardless of the esophago-gastric varix status. Although CSPH is defined as a hepatic venous pressure gradient (HVPG) >10 mmHg as the gold standard, liver stiffness measurement (LSM) using the transient elastography is recommended as a non-invasive alternative in clinical practice. $LSM \leq 10$ kPa in the absence of other clinical/image signs can rule out compensated advanced chronic liver disease, while $LSM \leq 15$ kPa plus platelet count $\geq 150 \times 10^9/L$ ($150,000/mm^3$) can rule out CSPH with a sensitivity and negative predictive value of >90% (3). Baveno VII omitted the indications for screening endoscopy in this category of patients. Contrasting with Baveno VII, Thabut and Kudo recommend screening endoscopy in patients with HCC, even in those with platelet count $\geq 150,000/mm^3$ and $LSM \leq 15$ kPa, considering that the criteria do not always rule out high-risk varices accurately. However, they agreed with Baveno VII in avoiding upper gastrointestinal endoscopy in HCC patients with $LSM > 25$ kPa receiving beta-blockers,

[^] ORCID: 0000-0002-1458-0689.

regardless of the esophageal variceal status. It is now widely recognized that beta-blockers, especially non-selective beta-blockers, reduce HCC-related mortality (5). They also argued that HCC patients with PHT should be monitored regularly, including the use of upper gastrointestinal endoscopies, since PHT may progress faster due to the occurrence of vascular invasion or worsening liver disease from HCC and its corresponding therapies (6). According to the report of the IMBrave 150 study, bleeding events occurred more frequently in the combination treatment with atezolizumab and bevacizumab group compared to the sorafenib group, even in well-selected patients (high-risk patients who developed PHT-related bleeding within six months before treatment were excluded) (7). Considering the increased bleeding risk associated with Bevacizumab use (8), Thabut and Kudo recommended a strict work-up of PHT before starting treatment with atezolizumab and bevacizumab in all patients and periodic surveillance more frequently than that recommended in patients without systemic therapy. They stated that, in their personal opinion, other regimens may be favored for patients with a history of bleeding from esophageal varices (4).

LSM by transient elastography is an excellent non-invasive and accurate diagnosis of cirrhosis (9). From the perspective of hepatic surgeons who perform surgery for HCC occasionally with PHT, several reports have suggested that LSM measurement can be useful in predicting complications and liver failure after hepatectomy (10-14). Kim *et al.* first showed the relationship between liver stiffness and postoperative liver failure (total bilirubin level >5 mg/dL for more than five days after surgery or postoperative death) and proposed a LSM cutoff value of 25.6 kPa (10). Cescon *et al.* suggested the cut-off value of LSM ≥ 15.7 kPa predicting the postoperative liver failure, which was mainly defined as: the occurrence of refractory ascites causing a delay in the removal of the drainage; an increase of bilirubin levels of more than 3 mg/dL; alteration of coagulation factors requiring fresh frozen plasma infusion, renal impairment, etc. (11). Furthermore, other researchers suggested the LSM cut-of values predicting postoperative liver failure according to the International Study Group of Liver Surgery definition (15) as 9.5–12 kPa (12-14). Rajakannu *et al.* defined persistent postoperative hepatic decompensation (PHD) as unresolved ascites, jaundice, and/or encephalopathy within three months after surgery and reported that LSM ≥ 22 kPa was strongly correlated with the occurrence of PHD (16). Although the cut-off values of LSM are variable and patient backgrounds

differ in each report, it is certain that LSM measurement is useful in predicting the development of complications after hepatic resection.

Our group has long argued that patients with HCC and PHT can undergo hepatic resection if the indication is carefully determined, and the complications associated with PHT are managed (17,18). However, the Barcelona Clinic Liver Cancer (BCLC) and other Western groups maintain that PHT is not an indication for hepatectomy (19). Although CSPH is defined as HVPG >10 mmHg, a strong correlation between HVPG and liver stiffness has been reported, and several reports on LSM values and the presence of CSPH have predicted LSM cut-off values of CSPH as 13.6–21.1 kPa (11,20-22). Robic *et al.* stated that LSM can help avoid unnecessary invasive hepatic vein catheterization and/or endoscopic screening or CSPH since LSM shows a strong correlation with HVPG (22), while Llop *et al.* reported that HVPG is still a non-replaceable method in detecting CSPH because. This is demonstrated in their validation report for each criterion, wherein LSM <13.6 kPa may have a high sensitivity but a low specificity, and LSM >21 kPa with a high specificity but a low sensitivity (23). Several studies have shown a relationship between indocyanine green (ICG) retention test and LSM. Fung *et al.* reviewed 44 liver resection cases and found that the ICG retention test at 15 min (ICG R15) and LSM had a significant correlation and were associated with early postoperative complications (24). Wong *et al.* stated that LSM is superior to ICG R15 in predicting postoperative complications in liver resection (25); however, LSM is still not a quantitative standard and is not comparable to a quantitative ICG test in determining the precise extent of resectability of a damaged liver (26).

LSM measurement is a non-invasive procedure that may replace HVPG in the diagnosis of PHT. As reported by Wu *et al.*, endoscopic screening prior to liver resection may be omitted in some patients according to the Baveno VII criteria (27), but the sensitivity of the diagnosis of risky varices is not 100%. We have encountered mortality due to variceal rupture in the perioperative period of liver resection (18). Therefore, for a safe liver resection, it is still recommended to perform endoscopy in patients with HCC associated with cirrhosis. We would also recommend endoscopic screening when administering bevacizumab to patients with HCC and cirrhosis, similar to the endoscopic procedure performed prior to liver resection. ICG R15 is also deemed essential in determining the extent of safe hepatic resection, but in the case of partial hepatic resection

with minimal loss of normal liver parenchyma, it may be possible to omit the ICG test in HCC with background liver damage within LSM ≤ 10 kPa, in the absence of other clinical/imaging signs described in the Baveno VII criteria. To gain widespread acceptance of our opinion that the presence of PHT is not a contraindication for hepatic resection, we need to continue to advocate for the possibility of hepatic resection of HCC with PHT presenting with LSM results.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, *Hepatobiliary Surgery and Nutrition*. The article did not undergo external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at <https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-598/coif>). N.K. serves as an unpaid editorial board member of *Hepatobiliary Surgery and Nutrition*. The other author has no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021;71:209-49.
- Kokudo N, Takemura N, Kanto T, et al. Hepatocellular carcinoma with non-B and non-C hepatitis origin: epidemiology in Japan and surgical outcome. *Glob Health Med* 2019;1:23-9.
- de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. *J Hepatol* 2022;76:959-74.
- Thabut D, Kudo M. Treatment of portal hypertension in patients with HCC in the era of Baveno VII. *J Hepatol* 2023;78:658-62.
- Udumyan R, Montgomery S, Duberg AS, et al. Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients. *Scand J Gastroenterol* 2020;55:597-605.
- Campion B, Larrey E, Wagner M, et al. Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "menage à trois" ! *Clin Res Hepatol Gastroenterol* 2022;46:101785.
- Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N Engl J Med* 2020;382:1894-905.
- Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. *J Clin Oncol* 2008;26:2992-8.
- Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. *Gastroenterology* 2008;134:960-74.
- Kim SU, Ahn SH, Park JY, et al. Prediction of postoperative hepatic insufficiency by liver stiffness measurement (FibroScan((R))) before curative resection of hepatocellular carcinoma: a pilot study. *Hepatol Int* 2008;2:471-7.
- Cescon M, Colecchia A, Cucchetti A, et al. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. *Ann Surg* 2012;256:706-12; discussion 712-3.
- Chong CC, Wong GL, Chan AW, et al. Liver stiffness measurement predicts high-grade post-hepatectomy liver failure: A prospective cohort study. *J Gastroenterol Hepatol* 2017;32:506-14.
- Shen Y, Zhou C, Zhu G, et al. Liver Stiffness Assessed by Shear Wave Elastography Predicts Postoperative Liver Failure in Patients with Hepatocellular Carcinoma. *J Gastrointest Surg* 2017;21:1471-9.
- Long H, Zhong X, Su L, et al. Liver Stiffness Measured by Two-Dimensional Shear Wave Elastography for

- Predicting Symptomatic Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. *Ann Surg Oncol* 2022;29:327-36.
15. Rahbari NN, Garden OJ, Padbury R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). *Surgery* 2011;149:713-24.
 16. Rajakannu M, Cherqui D, Ciaccio O, et al. Liver stiffness measurement by transient elastography predicts late posthepatectomy outcomes in patients undergoing resection for hepatocellular carcinoma. *Surgery* 2017;162:766-74.
 17. Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. *Gastroenterology* 2008;134:1908-16.
 18. Takemura N, Aoki T, Hasegawa K, et al. Hepatectomy for hepatocellular carcinoma after perioperative management of portal hypertension. *Br J Surg* 2019;106:1066-74.
 19. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. *J Hepatol* 2022;76:681-93.
 20. Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. *Hepatology* 2007;45:1290-7.
 21. Bureau C, Metivier S, Peron JM, et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. *Aliment Pharmacol Ther* 2008;27:1261-8.
 22. Robic MA, Procopet B, Métivier S, et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. *J Hepatol* 2011;55:1017-24.
 23. Llop E, Berzigotti A, Reig M, et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. *J Hepatol* 2012;56:103-8.
 24. Fung J, Poon RT, Yu WC, et al. Use of liver stiffness measurement for liver resection surgery: correlation with indocyanine green clearance testing and post-operative outcome. *PLoS One* 2013;8:e72306.
 25. Wong JS, Wong GL, Chan AW, et al. Liver stiffness measurement by transient elastography as a predictor on posthepatectomy outcomes. *Ann Surg* 2013;257:922-8.
 26. Mise Y, Hasegawa K, Satou S, et al. Venous reconstruction based on virtual liver resection to avoid congestion in the liver remnant. *Br J Surg* 2011;98:1742-51.
 27. Wu CW, Wong GL, Wong VW, et al. Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages. *J Gastroenterol Hepatol* 2023;38:1381-8.

Cite this article as: Takemura N, Kokudo N. Relationship between portal hypertension and liver stiffness measurements in the treatment of hepatocellular carcinoma from the surgeon's point of view in the Baveno VII era. *HepatoBiliary Surg Nutr* 2024;13(1):150-153. doi: 10.21037/hbsn-23-598